November 19, 2020
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual… Read More
learn more
November 11, 2020
Novocure Receives CE Mark for NovoTTF-100L™ System
The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer,… Read More
learn more
November 10, 2020
Novocure Announces Agenda for Virtual Research and Development Day
Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. Read More
learn more
November 9, 2020
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
Provides flexible capital structure prior to anticipated period of significant innovation and growth ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving… Read More
learn more
November 5, 2020
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement
Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million aggregate principal amount of… Read More
learn more
November 2, 2020
Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement
Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due… Read More
learn more
November 2, 2020
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will be offered in a… Read More
learn more
October 29, 2020
Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update
Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for… Read More
learn more
October 29, 2020
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are electric fields that disrupt… Read More
learn more
October 2, 2020
Novocure to Report Third Quarter 2020 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine… Read More
learn more